Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)

Summary

This is an open-labeled, no placebo, Phase IIa clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of one booster vaccine dose of SARS-CoV-2 DNA Vaccine (ICCOV) in adults aged 18 to 75 years who have received two to four dosese of COVID-19 vaccine.

Timeline

Start

2023-06-15

Primary completion

2023-12-31

Completion

2024-05-31

Publications

• Wong YC, Hang Ho DH, Zhou R, Zhang R, Woo KF, Cheng WY, Wang T, Du Y, Polly Pang KP, Tai WK, Jin X, Chen Z, Ngai Hung IF. An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19. EBioMedicine. 2025 May;115:105699. doi: 10.1016/j.ebiom.2025.105699. Epub 2025 Apr 16.

Drugs

Indications